Hovione
Hovione, a leading global provider of integrated solutions for the pharmaceutical industry, is headquartered in the United States with significant operations in Europe and Asia. Founded in 1959, the company has established itself as a key player in the development and manufacturing of active pharmaceutical ingredients (APIs) and drug products. Hovione is renowned for its expertise in spray drying and particle engineering, offering unique services that enhance drug solubility and bioavailability. With a strong commitment to quality and innovation, Hovione has achieved notable milestones, including successful collaborations with major pharmaceutical companies. The firm’s market position is bolstered by its comprehensive capabilities in formulation development, analytical services, and commercial manufacturing, making it a trusted partner in the pharmaceutical supply chain.
DitchCarbon Score
How does Hovione's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Furniture Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hovione's score of 7 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hovione's reported carbon emissions
Hovione's carbon emissions data reveals a significant environmental footprint, with total emissions reaching approximately 75,786,000 kg CO2e in 2022. This figure includes 17,421,000 kg CO2e from Scope 1 emissions, 11,920,000 kg CO2e from market-based Scope 2 emissions, and 46,445,000 kg CO2e from Scope 3 emissions. In the preceding years, emissions have shown a fluctuating trend: 70,089,000 kg CO2e in 2021, 65,244,000 kg CO2e in 2020, and 39,848,000 kg CO2e in 2019. Notably, the company reported 20,846,000 kg CO2e in Scope 1 emissions and 9,395,000 kg CO2e in market-based Scope 2 emissions for 2019. Hovione has committed to reducing its carbon footprint, although specific reduction targets have not been disclosed. The company is currently classified as "Committed" to near-term reduction targets, indicating an intention to implement strategies aimed at lowering emissions. However, it has not yet set a net-zero target. As a player in the Pharmaceuticals, Biotechnology, and Life Sciences sector, Hovione's climate commitments are crucial in addressing the industry's overall environmental impact. The company continues to monitor and report its emissions, reflecting a growing awareness of sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2014 | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,075,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,326,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 16,424,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hovione is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
